Identification | Back Directory | [Name]
Methyl 1-Cbz-azetidine-3-carboxylate | [CAS]
757239-60-4 | [Synonyms]
Methyl 1-Cbz-azetidine-3-... Methyl 1-Cbz-azetidine-3-carboxylate 1-benzyl 3-Methyl azetidine-1,3-dicarboxylate 1-Cbz-3-azetidinecarboxylic acid Methyl ester 1-CBZ-AZETIDINE-3-CARBOXYLIC ACID METHYL ESTER O1-benzyl O3-methyl azetidine-1,3-dicarboxylate Methyl 1-benzyloxycarbonylazetidine-3-carboxylate 1-benzyloxycarbonyl-3-azetidinecarboxylic acid methyl ester 1-Benzyloxycarbonyl-3-azetidinecarboxylic acid methyl ester 97% azetidine-1,3-dicarboxylic acid O3-methyl ester O1-(phenylmethyl) ester | [Molecular Formula]
C13H15NO4 | [MDL Number]
MFCD11110708 | [MOL File]
757239-60-4.mol | [Molecular Weight]
249.264 |
Hazard Information | Back Directory | [Uses]
Methyl 1-Cbz-azetidine-3-carboxylate is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Methyl 1-Cbz-azetidine-3-carboxylate is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1 | [Synthesis]
To a round-bottomed flask containing methyl azetidine-3-carboxylate hydrochloride (3 g, 20 mmol), THF (30 mL), and H2O (30 mL) was slowly added aqueous NaOH solution (4 M, 5 mL, 20 mmol) at 0 °C. Subsequently, benzyl chloroformate (2.84 mL, 20 mmol) was added dropwise at the same temperature. The reaction mixture was stirred vigorously at room temperature for 18 hours. Upon completion of the reaction, the mixture was concentrated in vacuum to remove the solvent. The residue was partitioned between Et2O (100 mL) and H2O (30 mL). The aqueous phase was back-extracted with Et2O (3 x 50 mL) and all organic phases were combined and dried with anhydrous Na2SO4. The dried organic phase was concentrated in vacuum to afford methyl 1-Cbz-azetidine-3-carboxylate (5 g, 99% yield) as a colorless oil, which was directly used in the subsequent reaction without further purification.1H NMR (400 MHz, CDCl3): δ 7.43-7.25 (m, 5H), 5.10 (s, 2H), 4.23-4.13 (m, 4H) , 3.74 (s, 3H), 3.38 (q, J=7.2Hz, 1H). | [IC 50]
Non-cleavable Linker | [References]
[1] Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337. DOI:10.1038/nrd.2016.268 [2] Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985. DOI:10.7554/eLife.57277 |
|
Company Name: |
Energy Chemical
|
Tel: |
021-021-58432009 400-005-6266 |
Website: |
http://www.energy-chemical.com |
|